Soros Fund Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Soros Fund Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-7,800	Closed	-$1.1M	–	251
2016 Q2	$1.1M	Buy	+7,800	New	+$1.15M	0.02%	126
2016 Q1	–	Sell	-3,200	Closed	-$450K	–	269
2015 Q4	$450K	Buy	+3,200	New	+$443K	0.01%	198
2014 Q2	–	Sell	-3,600	Closed	-$499K	–	406
2014 Q1	$499K	Buy	+3,600	New	+$542K	﹤0.01%	269

Other funds holding JAZZ

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Soros Fund Management's JAZZ Position: Q3 2016 in Review

Soros Fund Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2016, closing a stake of 7,800 shares — an estimated $1.1M sold.

Soros Fund Management first reported a position in JAZZ in Q1 2014 and held it in 3 quarters. The position peaked at $1.1M in Q2 2016. 325 funds tracked by Wall St. Rank hold JAZZ as of Q3 2016.

Soros Fund Management reported no remaining Jazz Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Soros Fund Management sold 7,800 Jazz Pharmaceuticals shares in Q3 2016, an estimated $1.1M.
Soros Fund Management first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 3 quarters.
Soros Fund Management's Jazz Pharmaceuticals position peaked at $1.1M in Q2 2016.
325 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2016.

Based on Soros Fund Management's 13F filing for Q3 2016, filed 14 Nov 2016.